Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Oct 20, 2020

SELL
$1.75 - $6.2 $19,250 - $68,200
-11,000 Closed
0 $0
Q2 2020

Jul 16, 2020

SELL
$0.91 - $2.36 $29,120 - $75,520
-32,000 Reduced 74.42%
11,000 $20,000
Q1 2020

Apr 17, 2020

BUY
$1.01 - $3.42 $43,430 - $147,060
43,000 New
43,000 $43,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $492M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Wedbush Securities Inc Portfolio

Follow Wedbush Securities Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wedbush Securities Inc with notifications on news.